Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Bonora

Showing results (1-10 of 302) with videos related to

Pageof 31
Sort By:
The New Microbiologica|February 25, 2025
Pharmacological determinants of BIC/FTC/TAF to achieve long term success: potency, genetic barrier and forgivenessStefano Bonora
Optics Express|June 17, 2009
Push-pull membrane mirrors for adaptive opticsStefano Bonora, Luca Poletto
AIDS Reviews|February 10, 2017
Use of Daclatasvir in HCV/HIV-Coinfected Patients in a Real-Life SettingStefano Bonora, Massimo Puoti
The Journal of Antimicrobial Chemotherapy|July 30, 2004
Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?Giovanni Di Perri, Stefano Bonora
Current Opinion in HIV and AIDS|April 18, 2009
Interactions between antiretroviral agents and those used to treat tuberculosisStefano Bonora, Giovanni Di Perri
Le Infezioni in Medicina|September 11, 2025
Extending follow-up visits in people with HIV (PWH) receiving bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) therapy: an expert opinionGiovanni Di Perri, Stefano Bonora
The New Microbiologica|November 19, 2024
Clinical Pharmacology of the Single Tablet Regimen Bictegravir/Emtricitabine/Tenofovir Alafenamide in the evolving era of antiretroviral therapiesGiovanni Di Perri, Stefano Bonora
Expert Opinion on Drug Metabolism & Toxicology|December 12, 2017
Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?Ilaria Motta, Andrea Calcagno, Stefano Bonora
Expert Opinion on Drug Metabolism & Toxicology|June 16, 2015
Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patientsAndrea Calcagno, Antonio D'Avolio, Stefano Bonora
Pharmacogenomics|April 5, 2016
What do we know about tailoring treatment with tenofovir?Andrea Calcagno, Giovanni Di Perri, Stefano Bonora
Pageof 31

Showing results (1-10 of 302) with videos related to

Sort By:
Pageof 31
The New Microbiologica|February 25, 2025
Pharmacological determinants of BIC/FTC/TAF to achieve long term success: potency, genetic barrier and forgivenessStefano Bonora
Optics Express|June 17, 2009
Push-pull membrane mirrors for adaptive opticsStefano Bonora, Luca Poletto
AIDS Reviews|February 10, 2017
Use of Daclatasvir in HCV/HIV-Coinfected Patients in a Real-Life SettingStefano Bonora, Massimo Puoti
The Journal of Antimicrobial Chemotherapy|July 30, 2004
Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?Giovanni Di Perri, Stefano Bonora
Current Opinion in HIV and AIDS|April 18, 2009
Interactions between antiretroviral agents and those used to treat tuberculosisStefano Bonora, Giovanni Di Perri
Le Infezioni in Medicina|September 11, 2025
Extending follow-up visits in people with HIV (PWH) receiving bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) therapy: an expert opinionGiovanni Di Perri, Stefano Bonora
The New Microbiologica|November 19, 2024
Clinical Pharmacology of the Single Tablet Regimen Bictegravir/Emtricitabine/Tenofovir Alafenamide in the evolving era of antiretroviral therapiesGiovanni Di Perri, Stefano Bonora
Expert Opinion on Drug Metabolism & Toxicology|December 12, 2017
Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?Ilaria Motta, Andrea Calcagno, Stefano Bonora
Expert Opinion on Drug Metabolism & Toxicology|June 16, 2015
Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patientsAndrea Calcagno, Antonio D'Avolio, Stefano Bonora
Pharmacogenomics|April 5, 2016
What do we know about tailoring treatment with tenofovir?Andrea Calcagno, Giovanni Di Perri, Stefano Bonora
Pageof 31